<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:7fbbd6df-61b4-4daa-93e1-3fa4f5a4d889,g:c307d8d3-5267-4f62-8599-541e166723b7,d:8e0a13299f9a419bbc8283d828627655--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>smmt-20230127</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i497afdd266c1420c82d1e68a73fa8ea8_D20230127-20230127" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjhlMGExMzI5OWY5YTQxOWJiYzgyODNkODI4NjI3NjU1L3NlYzo4ZTBhMTMyOTlmOWE0MTliYmM4MjgzZDgyODYyNzY1NV80L2ZyYWc6OGJhNjY1Y2MwODg1NGVmNTgwYzc5MjEwNTc3OTU4MDkvdGFibGU6MGJmYzc4YTJkOWNhNDNlYzg3MjUyNGU0NTY1N2JjZWQvdGFibGVyYW5nZTowYmZjNzhhMmQ5Y2E0M2VjODcyNTI0ZTQ1NjU3YmNlZF8wLTEtMS0xLTExNjA3Nw_d7a56b95-3ad8-4891-b064-3aec109b69a8">0001599298</ix:nonNumeric><ix:nonNumeric contextRef="i497afdd266c1420c82d1e68a73fa8ea8_D20230127-20230127" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjhlMGExMzI5OWY5YTQxOWJiYzgyODNkODI4NjI3NjU1L3NlYzo4ZTBhMTMyOTlmOWE0MTliYmM4MjgzZDgyODYyNzY1NV80L2ZyYWc6OGJhNjY1Y2MwODg1NGVmNTgwYzc5MjEwNTc3OTU4MDkvdGFibGU6MGJmYzc4YTJkOWNhNDNlYzg3MjUyNGU0NTY1N2JjZWQvdGFibGVyYW5nZTowYmZjNzhhMmQ5Y2E0M2VjODcyNTI0ZTQ1NjU3YmNlZF8xLTEtMS0xLTExNjA3Nw_d1048f69-e2a2-41f8-8c06-041ac3ca404c">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="smmt-20230127.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i497afdd266c1420c82d1e68a73fa8ea8_D20230127-20230127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-27</xbrli:startDate><xbrli:endDate>2023-01-27</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i8e0a13299f9a419bbc8283d828627655_1"></div><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Washington, D.C. 20549</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">FORM <ix:nonNumeric contextRef="i497afdd266c1420c82d1e68a73fa8ea8_D20230127-20230127" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjhlMGExMzI5OWY5YTQxOWJiYzgyODNkODI4NjI3NjU1L3NlYzo4ZTBhMTMyOTlmOWE0MTliYmM4MjgzZDgyODYyNzY1NV8xL2ZyYWc6ZWEzOTRlNjkwMDU4NGM0N2EzZGVjYjg3MzI2YWViYzgvdGV4dHJlZ2lvbjplYTM5NGU2OTAwNTg0YzQ3YTNkZWNiODczMjZhZWJjOF81NzYz_c6a354c8-1e64-4162-baec-a1def3e697f9">8-K</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date of Report (Date of Earliest Event Reported): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><ix:nonNumeric contextRef="i497afdd266c1420c82d1e68a73fa8ea8_D20230127-20230127" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjhlMGExMzI5OWY5YTQxOWJiYzgyODNkODI4NjI3NjU1L3NlYzo4ZTBhMTMyOTlmOWE0MTliYmM4MjgzZDgyODYyNzY1NV8xL2ZyYWc6ZWEzOTRlNjkwMDU4NGM0N2EzZGVjYjg3MzI2YWViYzgvdGV4dHJlZ2lvbjplYTM5NGU2OTAwNTg0YzQ3YTNkZWNiODczMjZhZWJjOF8yMjg_fc1f5463-d755-4629-a5cb-dc85ec8415f9">January 27, 2023</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></div><div style="padding-left:5.65pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.860%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i497afdd266c1420c82d1e68a73fa8ea8_D20230127-20230127" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjhlMGExMzI5OWY5YTQxOWJiYzgyODNkODI4NjI3NjU1L3NlYzo4ZTBhMTMyOTlmOWE0MTliYmM4MjgzZDgyODYyNzY1NV8xL2ZyYWc6ZWEzOTRlNjkwMDU4NGM0N2EzZGVjYjg3MzI2YWViYzgvdGFibGU6MjY4OGQ3OWUzYmNjNDZlMzgzYzBiMDRiZTk4YzI0OGUvdGFibGVyYW5nZToyNjg4ZDc5ZTNiY2M0NmUzODNjMGIwNGJlOThjMjQ4ZV8wLTAtMS0xLTExNjA3Nw_a101b645-316e-4bb2-8128-3e579fa1cdfb">Summit Therapeutics Inc.</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Exact Name of Registrant as Specified in Its Charter)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 4.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 4.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i497afdd266c1420c82d1e68a73fa8ea8_D20230127-20230127" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjhlMGExMzI5OWY5YTQxOWJiYzgyODNkODI4NjI3NjU1L3NlYzo4ZTBhMTMyOTlmOWE0MTliYmM4MjgzZDgyODYyNzY1NV8xL2ZyYWc6ZWEzOTRlNjkwMDU4NGM0N2EzZGVjYjg3MzI2YWViYzgvdGFibGU6MjY4OGQ3OWUzYmNjNDZlMzgzYzBiMDRiZTk4YzI0OGUvdGFibGVyYW5nZToyNjg4ZDc5ZTNiY2M0NmUzODNjMGIwNGJlOThjMjQ4ZV8zLTAtMS0xLTExNjA3Nw_f24c8ca0-9e24-49d9-baf1-d968797180e7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i497afdd266c1420c82d1e68a73fa8ea8_D20230127-20230127" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjhlMGExMzI5OWY5YTQxOWJiYzgyODNkODI4NjI3NjU1L3NlYzo4ZTBhMTMyOTlmOWE0MTliYmM4MjgzZDgyODYyNzY1NV8xL2ZyYWc6ZWEzOTRlNjkwMDU4NGM0N2EzZGVjYjg3MzI2YWViYzgvdGFibGU6MjY4OGQ3OWUzYmNjNDZlMzgzYzBiMDRiZTk4YzI0OGUvdGFibGVyYW5nZToyNjg4ZDc5ZTNiY2M0NmUzODNjMGIwNGJlOThjMjQ4ZV8zLTEtMS0xLTExNjA3Nw_394c4b19-e216-4f64-84a3-fa37f228a380">001-36866</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i497afdd266c1420c82d1e68a73fa8ea8_D20230127-20230127" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjhlMGExMzI5OWY5YTQxOWJiYzgyODNkODI4NjI3NjU1L3NlYzo4ZTBhMTMyOTlmOWE0MTliYmM4MjgzZDgyODYyNzY1NV8xL2ZyYWc6ZWEzOTRlNjkwMDU4NGM0N2EzZGVjYjg3MzI2YWViYzgvdGFibGU6MjY4OGQ3OWUzYmNjNDZlMzgzYzBiMDRiZTk4YzI0OGUvdGFibGVyYW5nZToyNjg4ZDc5ZTNiY2M0NmUzODNjMGIwNGJlOThjMjQ4ZV8zLTItMS0xLTExNjA3Nw_98fa10c8-0188-4a84-85da-b28c017b0a9c">37-1979717</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(State or Other Jurisdiction<br/>of Incorporation)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Commission<br/>File Number)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(IRS Employer<br/>Identification No.)</span></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 4.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i497afdd266c1420c82d1e68a73fa8ea8_D20230127-20230127" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjhlMGExMzI5OWY5YTQxOWJiYzgyODNkODI4NjI3NjU1L3NlYzo4ZTBhMTMyOTlmOWE0MTliYmM4MjgzZDgyODYyNzY1NV8xL2ZyYWc6ZWEzOTRlNjkwMDU4NGM0N2EzZGVjYjg3MzI2YWViYzgvdGFibGU6MjY4OGQ3OWUzYmNjNDZlMzgzYzBiMDRiZTk4YzI0OGUvdGFibGVyYW5nZToyNjg4ZDc5ZTNiY2M0NmUzODNjMGIwNGJlOThjMjQ4ZV82LTAtMS0xLTExNjA3Ny90ZXh0cmVnaW9uOjg5NDRjMmExN2U5NzQ5MTk5Y2Q4YjY5Njg1NzFkZWIwXzU_2ec00ea3-e47e-47ef-b5a4-9bcdf13d082d">2882 Sand Hill Road, Suite 106</ix:nonNumeric>, <ix:nonNumeric contextRef="i497afdd266c1420c82d1e68a73fa8ea8_D20230127-20230127" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjhlMGExMzI5OWY5YTQxOWJiYzgyODNkODI4NjI3NjU1L3NlYzo4ZTBhMTMyOTlmOWE0MTliYmM4MjgzZDgyODYyNzY1NV8xL2ZyYWc6ZWEzOTRlNjkwMDU4NGM0N2EzZGVjYjg3MzI2YWViYzgvdGFibGU6MjY4OGQ3OWUzYmNjNDZlMzgzYzBiMDRiZTk4YzI0OGUvdGFibGVyYW5nZToyNjg4ZDc5ZTNiY2M0NmUzODNjMGIwNGJlOThjMjQ4ZV82LTAtMS0xLTExNjA3Ny90ZXh0cmVnaW9uOjg5NDRjMmExN2U5NzQ5MTk5Y2Q4YjY5Njg1NzFkZWIwXzk_6f1e4a02-4805-46fe-b91c-249bf2adae90">Menlo Park</ix:nonNumeric>, <ix:nonNumeric contextRef="i497afdd266c1420c82d1e68a73fa8ea8_D20230127-20230127" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjhlMGExMzI5OWY5YTQxOWJiYzgyODNkODI4NjI3NjU1L3NlYzo4ZTBhMTMyOTlmOWE0MTliYmM4MjgzZDgyODYyNzY1NV8xL2ZyYWc6ZWEzOTRlNjkwMDU4NGM0N2EzZGVjYjg3MzI2YWViYzgvdGFibGU6MjY4OGQ3OWUzYmNjNDZlMzgzYzBiMDRiZTk4YzI0OGUvdGFibGVyYW5nZToyNjg4ZDc5ZTNiY2M0NmUzODNjMGIwNGJlOThjMjQ4ZV82LTAtMS0xLTExNjA3Ny90ZXh0cmVnaW9uOjg5NDRjMmExN2U5NzQ5MTk5Y2Q4YjY5Njg1NzFkZWIwXzEz_138cedf1-bccd-46d3-9fc1-ed7430ae3823">CA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i497afdd266c1420c82d1e68a73fa8ea8_D20230127-20230127" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjhlMGExMzI5OWY5YTQxOWJiYzgyODNkODI4NjI3NjU1L3NlYzo4ZTBhMTMyOTlmOWE0MTliYmM4MjgzZDgyODYyNzY1NV8xL2ZyYWc6ZWEzOTRlNjkwMDU4NGM0N2EzZGVjYjg3MzI2YWViYzgvdGFibGU6MjY4OGQ3OWUzYmNjNDZlMzgzYzBiMDRiZTk4YzI0OGUvdGFibGVyYW5nZToyNjg4ZDc5ZTNiY2M0NmUzODNjMGIwNGJlOThjMjQ4ZV82LTItMS0xLTExNjA3Nw_fd433f78-3c9e-4098-83ec-7a566f48d19f">94025</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Zip Code)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Registrant&#8217;s Telephone Number, Including Area Code: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><ix:nonNumeric contextRef="i497afdd266c1420c82d1e68a73fa8ea8_D20230127-20230127" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjhlMGExMzI5OWY5YTQxOWJiYzgyODNkODI4NjI3NjU1L3NlYzo4ZTBhMTMyOTlmOWE0MTliYmM4MjgzZDgyODYyNzY1NV8xL2ZyYWc6ZWEzOTRlNjkwMDU4NGM0N2EzZGVjYjg3MzI2YWViYzgvdGV4dHJlZ2lvbjplYTM5NGU2OTAwNTg0YzQ3YTNkZWNiODczMjZhZWJjOF8yODk_697f8a8e-18e2-4c02-a472-e4874bc99871">617</ix:nonNumeric>-<ix:nonNumeric contextRef="i497afdd266c1420c82d1e68a73fa8ea8_D20230127-20230127" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjhlMGExMzI5OWY5YTQxOWJiYzgyODNkODI4NjI3NjU1L3NlYzo4ZTBhMTMyOTlmOWE0MTliYmM4MjgzZDgyODYyNzY1NV8xL2ZyYWc6ZWEzOTRlNjkwMDU4NGM0N2EzZGVjYjg3MzI2YWViYzgvdGV4dHJlZ2lvbjplYTM5NGU2OTAwNTg0YzQ3YTNkZWNiODczMjZhZWJjOF81NzU3_71f5a180-4e70-4d9c-818a-6e48f235e4f7">514-7149</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></div><div style="padding-left:5.65pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Former Name or Former Address, If Changed Since Last Report)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> General Instruction A.2. below):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i497afdd266c1420c82d1e68a73fa8ea8_D20230127-20230127" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjhlMGExMzI5OWY5YTQxOWJiYzgyODNkODI4NjI3NjU1L3NlYzo4ZTBhMTMyOTlmOWE0MTliYmM4MjgzZDgyODYyNzY1NV8xL2ZyYWc6ZWEzOTRlNjkwMDU4NGM0N2EzZGVjYjg3MzI2YWViYzgvdGV4dHJlZ2lvbjplYTM5NGU2OTAwNTg0YzQ3YTNkZWNiODczMjZhZWJjOF81NzY1_621863c9-3ce8-414f-8b54-474b11908d52">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i497afdd266c1420c82d1e68a73fa8ea8_D20230127-20230127" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjhlMGExMzI5OWY5YTQxOWJiYzgyODNkODI4NjI3NjU1L3NlYzo4ZTBhMTMyOTlmOWE0MTliYmM4MjgzZDgyODYyNzY1NV8xL2ZyYWc6ZWEzOTRlNjkwMDU4NGM0N2EzZGVjYjg3MzI2YWViYzgvdGV4dHJlZ2lvbjplYTM5NGU2OTAwNTg0YzQ3YTNkZWNiODczMjZhZWJjOF81NzU4_fd6593e3-7507-4f4c-a1fb-1ad7827913fd">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i497afdd266c1420c82d1e68a73fa8ea8_D20230127-20230127" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjhlMGExMzI5OWY5YTQxOWJiYzgyODNkODI4NjI3NjU1L3NlYzo4ZTBhMTMyOTlmOWE0MTliYmM4MjgzZDgyODYyNzY1NV8xL2ZyYWc6ZWEzOTRlNjkwMDU4NGM0N2EzZGVjYjg3MzI2YWViYzgvdGV4dHJlZ2lvbjplYTM5NGU2OTAwNTg0YzQ3YTNkZWNiODczMjZhZWJjOF81NzU1_e6aef3ad-0b9d-4b5b-9041-73b722e5f722">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i497afdd266c1420c82d1e68a73fa8ea8_D20230127-20230127" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjhlMGExMzI5OWY5YTQxOWJiYzgyODNkODI4NjI3NjU1L3NlYzo4ZTBhMTMyOTlmOWE0MTliYmM4MjgzZDgyODYyNzY1NV8xL2ZyYWc6ZWEzOTRlNjkwMDU4NGM0N2EzZGVjYjg3MzI2YWViYzgvdGV4dHJlZ2lvbjplYTM5NGU2OTAwNTg0YzQ3YTNkZWNiODczMjZhZWJjOF81NzU2_14d563cf-2fa7-41f3-86e6-2675b221a4f5">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))&#160;</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="padding-left:6.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Title of Each Class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Name of Each Exchange on Which Registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i497afdd266c1420c82d1e68a73fa8ea8_D20230127-20230127" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjhlMGExMzI5OWY5YTQxOWJiYzgyODNkODI4NjI3NjU1L3NlYzo4ZTBhMTMyOTlmOWE0MTliYmM4MjgzZDgyODYyNzY1NV8xL2ZyYWc6ZWEzOTRlNjkwMDU4NGM0N2EzZGVjYjg3MzI2YWViYzgvdGFibGU6M2Y5NzRlZDY2ZTdhNDM0ZTllNGMwYzliZThiNGYxYWQvdGFibGVyYW5nZTozZjk3NGVkNjZlN2E0MzRlOWU0YzBjOWJlOGI0ZjFhZF8xLTAtMS0xLTExNjA3Nw_6be6f0b3-6933-43e8-9820-7feedd634a59">Common stock, $0.01&#160;par value per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i497afdd266c1420c82d1e68a73fa8ea8_D20230127-20230127" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjhlMGExMzI5OWY5YTQxOWJiYzgyODNkODI4NjI3NjU1L3NlYzo4ZTBhMTMyOTlmOWE0MTliYmM4MjgzZDgyODYyNzY1NV8xL2ZyYWc6ZWEzOTRlNjkwMDU4NGM0N2EzZGVjYjg3MzI2YWViYzgvdGFibGU6M2Y5NzRlZDY2ZTdhNDM0ZTllNGMwYzliZThiNGYxYWQvdGFibGVyYW5nZTozZjk3NGVkNjZlN2E0MzRlOWU0YzBjOWJlOGI0ZjFhZF8xLTEtMS0xLTExNjA3Nw_e79ff1f2-248d-455a-a9db-c98625775f33">SMMT</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i497afdd266c1420c82d1e68a73fa8ea8_D20230127-20230127" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjhlMGExMzI5OWY5YTQxOWJiYzgyODNkODI4NjI3NjU1L3NlYzo4ZTBhMTMyOTlmOWE0MTliYmM4MjgzZDgyODYyNzY1NV8xL2ZyYWc6ZWEzOTRlNjkwMDU4NGM0N2EzZGVjYjg3MzI2YWViYzgvdGFibGU6M2Y5NzRlZDY2ZTdhNDM0ZTllNGMwYzliZThiNGYxYWQvdGFibGVyYW5nZTozZjk3NGVkNjZlN2E0MzRlOWU0YzBjOWJlOGI0ZjFhZF8xLTItMS0xLTExNjA3Nw_f95c810a-abb1-4ac0-b71d-7a004fd4da08">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Emerging growth company </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i497afdd266c1420c82d1e68a73fa8ea8_D20230127-20230127" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjhlMGExMzI5OWY5YTQxOWJiYzgyODNkODI4NjI3NjU1L3NlYzo4ZTBhMTMyOTlmOWE0MTliYmM4MjgzZDgyODYyNzY1NV8xL2ZyYWc6ZWEzOTRlNjkwMDU4NGM0N2EzZGVjYjg3MzI2YWViYzgvdGV4dHJlZ2lvbjplYTM5NGU2OTAwNTg0YzQ3YTNkZWNiODczMjZhZWJjOF81NzYy_cdbbe425-2df1-460d-9e85-8e4198f75d78">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9744;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:14.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 8.01</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Other Events.</span></div></td></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with Summit Therapeutics Inc.&#8217;s (the &#8220;Company&#8221;) previously announced $500 million rights offering, which shall be available to all holders of record of the Company&#8217;s common stock, par value $0.01 (the &#8220;Common Stock&#8221;), the Company&#8217;s Board of Directors has set the record date for the distribution of rights as the close of market on February 6, 2023 (the &#8220;Record Date&#8221;). The Company intends to distribute to all holders of Common Stock as of the Record Date non-transferable subscription rights to purchase up to 476,190,476 shares of Common Stock at a price per share equal to the lesser of (i) $1.05 per share, or (ii) the volume weighted-average price of the Common Stock for the five consecutive trading days through and including the expiration date of the offering, currently contemplated to be March 1, 2023.  Assuming that the rights offering is fully subscribed, the Company will receive gross proceeds of up to $500 million, less expenses related to the rights offering.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company filed a registration statement (including a prospectus) on Form S-3 with the Securities and Exchange Commission (the "SEC") on December 21, 2022, as amended on January 23, 2023, which has not yet become effective. The registration statement covers, among other things, the rights offering to which this communication relates. Such securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. Before you invest, you should read the final prospectus in that registration statement, together with any prospectus supplement, that we will file prior to commencing any rights offering, and the documents incorporated by reference in the prospectus (or any prospectus supplement), as well as the other documents the Company has filed with the SEC for more complete information about the Company and the rights offering. You may get these documents for free by visiting EDGAR on the SEC&#8217;s website at www.sec.gov.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This communication does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. </span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:14.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 9.01</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial Statements and Exhibits.</span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(d) Exhibits</span></div><div><span><br/></span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.945%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3pt;padding-right:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Exhibit Number</span></div></td><td colspan="3" style="padding:2px 1pt 2px 4.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">104</span></td><td colspan="3" style="padding:2px 1pt 2px 4.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="text-align:center;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SIGNATURE</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.</span></div><div style="padding-left:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.907%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td colspan="6" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SUMMIT THERAPEUTICS&#160;INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td colspan="6" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td colspan="6" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date: January 27, 2023</span></td><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By:</span></td><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ Ankur Dhingra</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Principal Financial Officer)</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "smmt-20230127.htm", "description": "8-K", "secsgml_size_bytes": 38642}]
{"company-data": {"conformed-name": "Summit Therapeutics Inc.", "cik": "0001599298", "assigned-sic": "2834", "irs-number": "000000000", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-36866", "film-number": "23562763"}, "business-address": {"street1": "2882 SAND HILL ROAD", "street2": "SUITE 106", "city": "MENLO PARK", "state": "CA", "zip": "94025", "phone": "617-514-7149"}, "mail-address": {"street1": "2882 SAND HILL ROAD", "street2": "SUITE 106", "city": "MENLO PARK", "state": "CA", "zip": "94025"}, "former-company": [{"former-conformed-name": "Summit Therapeutics plc", "date-changed": "20150219"}, {"former-conformed-name": "Summit Corp plc", "date-changed": "20140205"}]}
smmt-20230127
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
January 27, 2023
Summit Therapeutics Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
001-36866
37-1979717
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
2882 Sand Hill Road, Suite 106
,
Menlo Park
,
CA
94025
(Address of Principal Executive Offices)
(Zip Code)
Registrant's Telephone Number, Including Area Code:
617
-
514-7149
Not applicable
(Former Name or Former Address, If Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Trading Symbol(s)
Name of Each Exchange on Which Registered
Common stock, $0.01 par value per share
SMMT
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 8.01
Other Events.
In connection with Summit Therapeutics Inc.'s (the "Company") previously announced $500 million rights offering, which shall be available to all holders of record of the Company's common stock, par value $0.01 (the "Common Stock"), the Company's Board of Directors has set the record date for the distribution of rights as the close of market on February 6, 2023 (the "Record Date"). The Company intends to distribute to all holders of Common Stock as of the Record Date non-transferable subscription rights to purchase up to 476,190,476 shares of Common Stock at a price per share equal to the lesser of (i) $1.05 per share, or (ii) the volume weighted-average price of the Common Stock for the five consecutive trading days through and including the expiration date of the offering, currently contemplated to be March 1, 2023.  Assuming that the rights offering is fully subscribed, the Company will receive gross proceeds of up to $500 million, less expenses related to the rights offering.
The Company filed a registration statement (including a prospectus) on Form S-3 with the Securities and Exchange Commission (the "SEC") on December 21, 2022, as amended on January 23, 2023, which has not yet become effective. The registration statement covers, among other things, the rights offering to which this communication relates. Such securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. Before you invest, you should read the final prospectus in that registration statement, together with any prospectus supplement, that we will file prior to commencing any rights offering, and the documents incorporated by reference in the prospectus (or any prospectus supplement), as well as the other documents the Company has filed with the SEC for more complete information about the Company and the rights offering. You may get these documents for free by visiting EDGAR on the SEC's website at www.sec.gov.
This communication does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits
Exhibit Number
Description
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
SUMMIT THERAPEUTICS INC.
Date: January 27, 2023
By:
/s/ Ankur Dhingra
Chief Financial Officer
(Principal Financial Officer)